37 results
6-K
EX-99.1
TAK
Takeda Pharmaceutical Co
29 May 24
Current report (foreign)
6:29am
our operations and across our value chain is at the heart of our initiatives, whether through reducing energy use, switching to renewable energy
6-K
EX-99.1
TAK
Takeda Pharmaceutical Co
29 May 24
Current report (foreign)
6:29am
exposure to fluctuations in prices of renewable energy using forward contracts. Takeda does not enter into derivative transactions for trading … between the fixed prices and floating market prices of renewable energy in a virtual power purchase agreement and those recognized in an agreement
6-K
TAK
Takeda Pharmaceutical Co
2 Feb 24
Current report (foreign)
6:16am
arising from differences between the fixed prices and floating market prices of renewable energy in a virtual power purchase agreement and those … method. The key assumptions taken into account include forecasted renewable energy prices and the expected generation of the renewable energy
6-K
TAK
Takeda Pharmaceutical Co
1 Feb 24
Current report (foreign)
6:18am
in renewable energy or low carbon energy technology will enable us to reduce our greenhouse gas emissions; and other factors identified in Takeda’s most
6-K
EX-99.1
TAK
Takeda Pharmaceutical Co
1 Feb 24
Current report (foreign)
6:06am
energy conservation measures and future advancements in renewable energy or low carbon energy technology will enable us to reduce our greenhouse gas
6-K
EX-99.1
uourb4cp1i90ww2kll
30 Nov 23
Current report (foreign)
6:01am
6-K
r15s7h6g3jh4w7wk5 zp
30 Oct 23
Current report (foreign)
6:02am
6-K
EX-99.1
yaj9rp7 rf04l53
30 Oct 23
Current report (foreign)
6:02am
6-K
EX-99.1
lttwhvssevuyutx3xok
26 Oct 23
Current report (foreign)
6:20am
6-K
o2f5yx zv
1 Aug 23
Current report (foreign)
6:10am
6-K
EX-99.1
su3dhfdt
27 Jul 23
Current report (foreign)
6:05am
6-K
EX-99.1
cr2q9
6 Jul 23
Current report (foreign)
6:18am
6-K
EX-99.1
tfuiu1qw
23 Jun 23
Current report (foreign)
6:13am
6-K
EX-99.1
1pzat
30 May 23
Current report (foreign)
6:19am
6-K
EX-99.1
uelu6ttji2fgyw ch17
30 May 23
Current report (foreign)
6:14am
6-K
EX-99.1
rvufsj4 nb4so
30 May 23
Current report (foreign)
6:11am
6-K
98a bwkwer
11 May 23
Current report (foreign)
6:07am
6-K
EX-99.1
rahj0kxp
11 May 23
Current report (foreign)
6:07am
6-K
fb3j 05ukj44wvo
13 Dec 22
Takeda to Acquire Late-Stage, Potential Best-in-Class, Oral Allosteric TYK2 Inhibitor NDI-034858 From Nimbus Therapeutics
7:00am